The Scleroderma Education Project recently released guidelines for patients and doctors wishing to know more about therapeutic plasma exchange (TPE) as a treatment option for limited scleroderma. The guidelines are designed to facilitate data collection to support the launch of a randomized clinical trial, and follow the same setup as…
News
Project Scleroderma: Beneath the Surface has recently gained popularity, it was presented on the Oprah show and is highly anticipated by the scleroderma community. But what is this project and how was it started? Christy McCaffrey lost her mother to scleroderma in September of 2009 and she began…
A woman with metastatic colorectal cancer treated with the chemotherapy drug Xeloda (capecitabine) developed diffuse scleroderma — a condition never before linked to the use of this particular cancer drug. The study, “Scleroderma in a Patient on Capecitabine: Is this a Variant of Hand-Foot Syndrome?,” published in the…
Esbriet (pirfenidone) has an acceptable level of tolerability in patients with systemic sclerosis (SSc) associated with interstitial lung disease (ILD), and may be tested for efficacy in future clinical trials in these patients, according to the results of a randomized Phase 2 study, the LOTUSS trial. The study, “An…
A study showed the effectiveness of hydrogen sulfide in a mouse model of scleroderma, and researchers in China suggest that the compound should be explored as a potential treatment for patients. The study, “The protective effect of hydrogen sulfide on systemic sclerosis associated skin and lung fibrosis in mice model,” published…
Scleroderma patients with pulmonary arterial hypertension (PAH) benefit equally well from treatment with Adempas (riociguat) as PAH patients with other types of connective tissue disease (PAH-CTD), according to research from the University of Paris-Saclay in France. The study, “Riociguat for the treatment of pulmonary arterial hypertension…
This week, Scleroderma News reported on the recent study, “Watermelon stomach and colon in a patient with diffuse cutaneous systemic sclerosis,” published in the journal Modern Rheumatology. The news article informs us that: ‘GI complications, such as hemorrhages, low esophageal motility, and bacterial overgrowth, are common in…
A direct comparison of Cytoxan (Cyclophosphamide) and Cellcept (mycophenolate mofetil) showed that the drugs are equally effective in stabilizing, and even improving, lung function in scleroderma patients with lung fibrosis. Since Cytoxan might be more toxic when used for extended periods, the study, “Cyclophosphamide versus mycophenolate mofetil…
Systemic sclerosis may lead to the appearance of gastrointestinal (GI) lesions that resemble the stripes of a watermelon, which explains the expression “watermelon stomach.” Although it is often restricted to the stomach, researchers presented, for what is believed to be the first time, a case of watermelon stomach and colon.
A case study, describing the successful treatment of a scleroderma patient with repeated therapeutic plasma exchange (TPE) for more than 22 years, presents an alternative theory about the beneficial effects of the treatment and the disease itself. The study “Successful long-term (22 Year) treatment of limited scleroderma…
Recent Posts
- New scleroderma survey seeks patient input to guide future research
- Scleroderma added to NIH project targeting autoimmune diseases
- Off-the-shelf cell therapy shows early promise as scleroderma treatment
- Trial to test scleroderma treatments at earliest stages of disease
- Off-label JAK inhibitors may stabilize lung function in systemic sclerosis
- Distinct symptom pattern found for triple-negative scleroderma patients
- Plant-based nanoparticle therapy eases skin thickening in SSc: Study
- Specialized MRI scans may catch early lung damage in scleroderma
- Spotlighting ‘Beacons of Hope’ for this year’s Scleroderma Awareness Month
- Fewer capillaries in hands may contribute to scleroderma bone loss